However analysis of clinical data argue against Ago2-dependent STIM1 upregulation as a consistent mechanism supporting breast cancer progression, because even in the most aggressive basal-like subtype there is no negative correlation between Ago2 and STIM1 expression. Here, STIM1 is linked to breast carcinoma.